Allucent

Allucent's Formation and Evolution

Allucent was formed in the spring of 2022 through the strategic merger of several high-performance companies specializing in the needs of small and mid-sized biotechs. Its roots trace back to CATO SMS, which itself resulted from the 2019 merger of Cato Research and SMS-oncology. SMS-oncology, founded in 2007, was known for its comprehensive clinical trial services and strategic consulting in oncology. The merger of CATO SMS with Pharm-Olam in early 2022 solidified Allucent's global presence in the clinical research sector. This consolidation has enabled Allucent to leverage a broad range of expertise and resources to support complex drug development efforts.

Allucent's Expertise and Services

Allucent focuses on advanced areas of drug development, including oncology, rare and orphan indications, and cell and gene therapies. The company offers a wide array of services such as regulatory strategy, clinical trial design, and product development. Their offerings include regulatory intelligence, global strategy, IND and NDA submissions, orphan drug designation, and pediatric investigation plans. Allucent's strong preclinical capabilities encompass both in vitro and in vivo studies, and they provide extensive data management and analysis services that are crucial for decision-making and regulatory submissions. The firm’s expertise ensures comprehensive support in drug candidate identification and validation.

Allucent's Global Reach and Clinical Trials

With a global footprint that includes offices across North America, Europe, and the Middle East, Allucent has conducted clinical trials in more than 60 countries. The company has a robust portfolio of over 700 clinical trials, a majority of which are in oncology. Allucent has proven capabilities in managing large-scale Phase III clinical trials and offers specialized services such as first-in-human, dose-escalation, and proof-of-concept trial designs. Their global reach and extensive trial experience make them a trusted partner in advancing complex drug development projects.

Allucent's Biostatistics and Data Services

Array Biostatistics, a part of Allucent, provides full-service biostatistical and statistical programming support. These services are critical for ensuring the accuracy and integrity of clinical trial data, which in turn support robust decision-making and regulatory submissions. Allucent’s data management services include sophisticated data collection, management, and analysis techniques that are essential for the successful execution of clinical trials. Their ability to deliver precise and reliable data analytics makes them a valuable partner in the biotech and pharmaceutical industries.

Allucent's Industry Recognition

Allucent has garnered significant recognition within the industry, including being named one of India’s Best Workplaces in Pharmaceuticals, Healthcare, and Biotech in 2023. This accolade reflects the company's commitment to fostering a positive work environment and driving innovation in the biotech sector. Such recognition underscores Allucent's dedication to excellence in both its internal operations and its contributions to the broader industry, further establishing its reputation as a leader in specialized clinical research and drug development services.